Combined l-/t-type calcium channel blockers ready for prime time

Hypertension

Volumn 53, Issue 4, 2009, Pages 592-594

  Ge, Wei ^a   Ren, Jun ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; DILTIAZEM; EFONIDIPINE; MANIDIPINE; MIBEFRADIL; NIFEDIPINE; NILVADIPINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CELL PROLIFERATION; DRUG EFFICACY; EDITORIAL; ENDOCRINE CELL; HEART EDEMA; HEART MUSCLE CELL; HORMONE RELEASE; HYPERTENSION; KIDNEY FUNCTION; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; TACHYCARDIA; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

CALCIUM CHANNELS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; HUMANS; HYPERTENSION;

EID: 64849099219     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.127548     Document Type: Editorial

References (10)

1. McGivern JG. Pharmacology and drug discovery for T-type calcium channels. CNS Neurol Disord Drug Targets. 2006;5:587-603.
2. 2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007; 100: 342-353.
3. Richard S. Vascular effects of calcium channel antagonists: new evidence. Drug. 2005;65:1-10.
4. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev. 2003;83:117-161.
5. 2+ channels. Am J Physiol Heart Circ Physiol. 20Ol;280:H582-H590.
6. Ball CJ, Wilson DP, Turner SP, Saint DA, Beltrame JF. Heterogeneity of L- and T-channels in the vasculature: rationale for the efficacy of combined L- and T-blockade. Hypertension. 2009;53:654-660.
7. Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. Hypertens Res. 2007;30:797-806.
8. Oshima T, Ozono R, Yano Y, Higashi Y, Teragawa H, Miho N, Ishida T, Ishida M, Yoshizumi M, Kambe M. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension. Hypertens Res. 2005;28:889-894.
9. Major TC, Dhamija S, Black N, Liachenko S, Morenko B, Sobocinski G, Okerberg C, Tinholt P, Madore S, Kowala MC. The T- and L-type calcium channel blocker (CCB) mibefradil attenuates leg edema induced by the L-type CCB nifedipine in the spontaneously hypertensive rat: a novel differentiating assay. J Pharmacol Exp Ther. 2008;325:723-731.
10. Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs. 2007;67: 1309-1327.